The Weekly Checkup · August 25, 2026

The Weekly Checkup: Week of August 17-21, 2026

The Pulse

Busier week than last. I tracked 47 announced transactions, with 27 services and 20 technology, and four platform deal against 44 add-ons plus 2 SPAC-style reverse mergers, which flips the mix from last week's tech-heavy tilt. Two deals came through with full financial disclosure that were willing to discuss here: Francisco Partners is taking Weave Communications private for $650 million, a rich multiple on thin margin, and DocGo is picking up Hicuity Health mostly by assuming its debt. BioMarin bought Alesta Therapeutics for a Phase 1/2a rare bone disease asset using the same spin-out structure Jazz used on Actio last week, and Advanced Recovery Systems bought a distressed competitor months after abandoning its own sale process.

Listings run from a probably legitimate AI-powered hair restoration device maker to a statistics focused pharma consultancy to a large California full-service clinical laboratory.

🤝 Announced Deals

Francisco Partners takes Weave Communications private

Deal value: $650 million | EV / Revenue: 2.44x | EV / EBITDA: 39.19x

Francisco Partners agreed to acquire Weave Communications, a patient-engagement and payments platform used by more than 40,000 healthcare practice locations, for $7.40 per share in cash, a 34% premium to the unaffected price. Against annualized 2026 revenue of $266.1 million and adjusted EBITDA of $16.6 million, a 6.2% margin, that works out to 2.44x revenue and 39.19x EBITDA. Close is expected in Q4 2026.

My take: A 39x EBITDA multiple looks alarming until you notice the denominator is only $16.6 million on $266 million of revenue. At a 6.2% margin, EBITDA is nearly irrelevant to how this deal actually got priced, and 2.44x revenue is the more relevant number, especially since Weave turned profitable just a short time ago. The revenue multiple isn’t a rich one (at all), for vertical healthcare SaaS with 40,000 locations of embedded, hard-to-switch distribution that has been growing in the 15% to 20% range annually the last few years. Francisco Partners is betting it can push Weave's margin toward the mature vertical SaaS realm, likely by layering payments and revenue-cycle attach rates onto an already-installed base.

DocGo acquires Hicuity Health, assumes $52 million of debt

Deal value: $53.3 million | EV / Revenue: 0.82x | EV / EBITDA: 11.84x

DocGo agreed to acquire Hicuity Health, a tele-ICU, virtual nursing, and telemetry monitoring provider with more than 400 clinical staff, on a cash-free basis by assuming approximately $52 million of Hicuity's existing debt to lender Perceptive Advisors. Hicuity's preferred shareholder gets DocGo stock equal to 2% of shares outstanding, with a possible additional 3.5% if DocGo's market cap reaches $250 million within three years. On a trailing 12-month basis Hicuity generated $65 million of revenue and $4.5 million of adjusted EBITDA. Perceptive separately committed up to $50 million in new financing to DocGo.

My take: Nobody wrote a check here. DocGo took on Hicuity's debt, handed the preferred holder a sliver of DocGo stock that mostly converts to meaningful value only if DocGo's own stock triples, and got Perceptive to agree to keep lending. That's a lender-driven restructuring in an M&A press release. Tele-ICU demand is durable: rural and community hospitals can't hire enough intensivists, and a 400-person clinical staff with hospital relationships is worth something. But DocGo also cut its own FY26 EBITDA guidance the same day, so this is a distressed lender consolidating two credits it's already exposed to rather than a buyer paying up for a strategic asset. Watch for more of these debt-for-equity healthcare tech deals as venture-backed outfits run out of runway.

BioMarin acquires Alesta Therapeutics for its hypophosphatasia asset

Deal value: $275 million upfront, up to $215 million in milestones

BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in development and regulatory milestones, gaining ALE1, a Phase 1/2a oral small molecule for hypophosphatasia, a rare genetic bone disease currently treated only by injectable enzyme replacement therapy. Alesta will spin out its non-ALE1 programs, including a Charcot-Marie-Tooth asset, to a new entity before closing, and none of Alesta's employees are joining BioMarin. The deal is BioMarin's third major rare disease acquisition in the past year, after the $4.8 billion purchase of Amicus Therapeutics.

My take: Same playbook as Jazz and Actio last week, down to the mechanics: spin the rest of the pipeline into a new company, transfer the employees there, and let the acquirer pay only for the one asset it wants. That structure is becoming the default way clinical-stage biotechs get bought. BioMarin just killed an enzyme-replacement program for a related bone disease (ENPP1 deficiency) after a failed Phase 3, acquired last year for $270 million through the Inozyme deal. Buying an oral alternative in an adjacent rare bone disease within months of that failure seems to indicate that BioMarin is a true believer in the therapeutic area and is making a commitment to using the format that worked (oral, not injectable). $275 million upfront for a Phase 1/2a asset is a bet BioMarin is comfortable enough with early data to write a nine-figure check before a single efficacy readout in HPP patients.

Advanced Recovery Systems acquires Promises Behavioral Health

Advanced Recovery Systems, a Goldman Sachs Asset Management-backed addiction treatment platform, acquired Promises Behavioral Health, creating a combined company operating 24 addiction and mental-health facilities across 14 states. Promises closed three facilities in late 2026, affecting 122 employees, ahead of the deal. In January, Goldman had halted its own sale process for Advanced Recovery Systems after failing to find a buyer at its target price.

My take: This is consolidation by attrition, not by growth thesis. Addiction treatment M&A is down sharply this year, six deals in the first half of 2026 against 19 in the same period last year, a 68% drop, and the platforms that would normally be exit candidates are instead becoming acquirers of their distressed peers. Goldman tried to sell Advanced Recovery Systems, couldn't clear its price, and pivoted to buying a smaller platform that was already closing facilities instead. That's not a vote of confidence in the sector's near-term multiple; it's a sponsor extending its hold period by adding scale it hopes will be worth more later, or at least worth more than sitting on a platform nobody wanted to buy. For owners of addiction treatment facilities watching this from the sidelines, the read is that near-term buyer appetite is thin and consolidators are shopping for distress, not paying full multiples for healthy assets. If you're not under financial pressure to sell, this isn't the year to test the market.

I tracked 43 additional transactions this week, including R1 RCM's acquisition of prior-authorization AI company Humata Health, Orthopaedic Solutions Management's 23rd partnership with Orlando Orthopaedic Center, a 24-physician group, Surgery Partners' addition of North Florida Cataract Specialists, and Straine Dental Management's entry into its 17th state with a dentist-owned Idaho practice. On the hospital side, Bon Secours Mercy Health added Fauquier Health in Virginia while BradenHealth took over Jellico Regional, a rural Tennessee hospital reopening after years of closure risk. The complete list, with the financial detail Scope is known for, is available to clients.

🏷️ Active Listings: Businesses You Can Actually Buy

Same exercise as always: figure out what each earnings line is measuring before arguing about the multiple.

1. AI-Powered Robotic Hair Transplant Device Company, Tampa

SBA pre-qualified MedTech company, established in 2018, developing AI and AR-assisted robotic systems for hair restoration, sold to physicians, clinics, and entrepreneurs entering the hair transplant business. The listing cites 22 granted patents, 80-85% gross margins, three core product models at different automation tiers, and an average deal size of $110,000 per unit sold.

My take: This is a device manufacturer, not a clinic, and that distinction matters for how you underwrite it. The buyer here isn't purchasing patient revenue, they're purchasing a capital equipment sales business competing against an established incumbent (Restoration Robotics' ARTAS system, now under Venus Concept) in a niche that's grown from a novelty into a legitimate category over the past decade. A 70% cash flow margin on equipment sales is plausible if the units are largely software and assembled hardware with outsourced manufacturing, but confirm what's actually included in COGS versus what's capitalized, and get the patent portfolio reviewed independently, since 22 granted claims sounds impressive until you know how many are core versus peripheral. The real diligence question is customer concentration and reorder rates: does revenue come from a broad base of independent clinics buying one unit each, or a handful of larger accounts, and is there a consumables or service-contract tail once a unit sells, or is each sale a one-time transaction that requires constant new customer acquisition. SBA pre-qualification with a 10% down payment option widens the buyer pool meaningfully at this price point.

2. Occupational Medical Testing Company, Florida

Occupational health clinic specialized in workplace drug-testing and loss-prevention programs, explicitly not a lab, providing mobile testing services to large corporations across the U.S.

My take: The listing's insistence that this is "not a lab" is interesting. Clinical laboratories carry CLIA certification requirements, PAMA reimbursement exposure, and a CHOW process on any change of ownership if they bill Medicare or Medicaid. A testing coordination business that contracts out actual specimen analysis and focuses on employer-paid drug screening and mobile collection sidesteps most of that regulatory overhead, which is a meaningfully simpler asset to acquire and integrate. The 36% margin and 1.2x revenue multiple are both reasonable for a services business with corporate B2B contracts rather than payer reimbursement risk. The diligence priorities: contract terms and renewal cadence with the large-corporation client base (are these annual RFPs or evergreen agreements), how mobile testing logistics scale with new geography, and whether "large corporations" means five accounts or fifty, since concentration risk in a B2B services model like this one is often an issue. Concentra's acquisition of four Minnesota occupational health centers this same week is a reminder that strategic buyers (and quietly, private equity sponsors) are actively building in this category right now.

3. 20M Growing Full-Service Medical Laboratory, Los Angeles

Full-menu clinical laboratory contracted with major insurance networks, over 10,000 square feet, approximately 200 employees, described as growing daily with new accounts. Owner willing to stay on post-close. Equipment valued at over $1 million included, roughly $150,000 of inventory, seller financing available for qualified buyers.

My take: In-network contracts are a big selling point here, and they're also the entire risk. A full-service lab with established payer contracts is pretty hard to replicate; getting a new lab credentialed and in-network with major commercial insurers can take a year or more, so a buyer is paying for time saved as much as for current earnings. But labs are also where PAMA reimbursement cuts, prior authorization tightening, and payer audit activity concentrate more than almost anywhere else in healthcare services, so the 30% margin needs to be stress-tested against a scenario where one or two payer contracts get repriced or terminated. At 7.0x cash flow for a lab of this scale, this sits in the middle of where full-service labs with payer diversification have traded, not a bargain, not obviously rich. Ask for a payer-by-payer revenue breakdown, not just a blended average, and get current standing confirmed directly with each major carrier rather than relying on the seller's characterization of the relationships.

4. Pharmaceutical and Biotech Statistical Consulting Firm, PA/CA

Statistical consulting firm founded in 1993 supporting clinical research data analysis and reporting for pharmaceutical and biotech clients pursuing FDA drug approval. Revenue grew from $5.26 million in 2019 to a projected $10.7 million in 2024, with EBITDA projected at $2.4 million, up from $873,000 in 2019. Owner pursuing semi-retirement, willing to stay on transitionally or as a part-time consultant.

My take: Thirty-plus years of FDA statistical consulting relationships is a pretty durable position in a niche that doesn't show up in most people's mental map of healthcare M&A, but the growth trajectory is the number worth sitting with. Revenue roughly doubled from 2019 to 2022 (26% and 25% growth in consecutive years) before decelerating, and EBITDA margin actually compressed over the same window, from about 16.6% in 2019 to a projected 22.4% in 2024 after dipping into the low teens in between, which suggests the firm added headcount and infrastructure ahead of revenue in the growth years and is only now catching back up on margin. That's a normal scaling pattern for a professional services firm, not a red flag by itself, but a buyer should get the client list and understand concentration, since FDA statistical consulting work often clusters around a handful of large pharma relationships that can be lumpy project-to-project. Regulatory and quality-systems consulting has been an active category lately too. FDAQRC bought Compliance Architects this same week for the same kind of expertise, so strategic appetite for this niche looks very much alive right now.

5. Dental Laboratory with 30+ Technicians, Kings County, New York

Dental laboratory founded in 2007, employing over 30 skilled technicians, producing crowns, bridges, implants, removable appliances, and ceramic restorations for dental practices.

My take: Dental labs sit one level removed from all the DSO consolidation this newsletter covers most weeks, and they're worth examining separately because the buyer logic is a bit different. A lab isn't licensed the way a dental practice is, there's no CPOM issue, and the customer base is other dental practices rather than patients, so this is closer to a specialty manufacturing business than a healthcare services roll-up target. The real question is digital workflow exposure: intraoral scanning, in-house milling, and same-day crown systems have been steadily pulling simple restorative cases in-house at the practice level for a decade, which shrinks the addressable market for outside labs even as complex cases (implants, full-arch, ceramic work requiring real craftsmanship) continue to grow. Thirty-plus technicians is a large, skilled labor force to retain through a transition, and technician turnover risk should be a top diligence item. At 6.3x cash flow for a business this size, this is priced on the high-end for a stable, mature business rather vs. a growth story, but it’s probably correct.

Sign-Off

Thanks for the read, and let me know what you think!

Will

The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Access to Scope Research healthcare M&A databases or valuation consulting engagements through HealthFMV require a separate agreement.

Get the next one in your inbox

Subscribe free